Placeholder canvas

Bharat Biotech announces India’s first COVID-19 vaccine candidate ‘COVAXIN’ with DCGI approval for human clinical trials

Date:

Hyderabad-based Bharat Biotech announced that it has successfully developed Covaxin, India’s first vaccine candidate for Covid-19, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

BharatBio
The Drug Controller General of India – CDSCO, Ministry of Health & Family Welfare granted permission to initiate Phase I & II Human clinical trials after the company submitted results generated from preclinical studies, demonstrating safety and immune response. Human clinical trials are scheduled to start across India in July 2020. The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech.

The indigenous, inactivated vaccine developed and manufactured in the company’s Bio-Safety Level 3 (BSL-3) High Containment facility located in Genome Valley, Hyderabad.
Announcing the vaccine development milestone, Dr Krishna Ella, Chairman and Managing Director said: “We are proud to announce COVAXIN, India’s first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine.”

Dr Ella added, “The proactive support and guidance from CDSCO has enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform.”

Expedited through national regulatory protocols, the company accelerated its objective in completing the comprehensive pre-clinical studies. Results from these studies have been promising and show extensive safety and effective immune responses.

Speaking about Bharat Biotech’s prowess, Suchitra Ella, Joint Managing Director said, “Our ongoing research and expertise in forecasting epidemics has enabled us to successfully manufacture a vaccine for the H1N1 pandemic.”

“Continuing our focus on creating the only BSL-3 containment facilities for manufacturing and testing in India, Bharat Biotech is committed to advancing vaccine development as a matter of national importance to demonstrate India’s strength in handling future pandemics,” she added.

Bharat Biotech’s track record in developing vero cell culture platform technologies has been proven in several vaccines for Polio, Rabies, Rotavirus, Japanese Encephalitis, Chikungunya and Zika.

Click here for Latest News updates and viral videos on our AI-powered smart news

For viral videos and Latest trends subscribe to NewsMobile YouTube Channel and Follow us on Instagram

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

Popular

More like this
Related

NIA Arrests One Key Conspirator In Rameshwaram Cafe Blast Case

New Delhi: In a significant development in the investigation...

H1B Visa: USCIS Gears Up For Lottery Selection For Fy-25

Due to a technical issue with its website, the USCIS delayed the deadline for visa applications for the financial year 2025 by three days from March 22nd to March 25th, 2024

To Browbeat And Bully Others Is Vintage Congress Culture: PM Modi After 600 Lawyers Write CJI

New Delhi: In response to the voiced apprehensions of...

Allu Arjun’s ‘Pushpa’ Saga: Trilogy Confirmed with ‘The Roar’ Title

As the dust settles from the electrifying release of...